IP Library Granted Patent US 9,849,169
Granted Patent B2
US 9,849,169 · App. 14/651,156 · Granted Dec 26, 2017

MDR

Inventors: Eszter Nagy (Vienna, AT); Gábor Nagy (Sopron, HU); Valéria Szijárto (Vienna, AT); Zoltán Magyarics (Vienna, AT); Irina Mirkina (Vienna, AT); Luis Guachalla (Vienna, AT); Adriana Badarau (Vienna, AT); Gerhild Zauner (Vienna, AT); Jolanta Lukasiewicz (Wroclaw, PL)
Assignee: ARSANIS Biosciences GmbH
A61K39/0258C07K16/1232G01N33/56916A61K2039/505A61K2039/55505A61K2039/55511A61K2039/55561C07K2317/33C07K2317/73C07K2317/92G01N2333/245G01N2469/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,849,169
App. No.
14/651,156
Granted
Dec 26, 2017
Kind
B2
Abstract

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Claims (15)

1. A monoclonal antibody composition comprising:

an isolated monoclonal antibody that specifically binds to 025b antigen of multi drug resistant (MDR) E. coli strains, and

a carrier or excipient.

2. A monoclonal antibody composition comprising:

a) an isolated monoclonal antibody that specifically binds to 025b antigen of multi drug resistant (MDR) E. coli strains which comprises:

the variable region of the antibody light chain produced by the host cell deposited under DSM 26763; and

the variable region of the antibody heavy chain produced by the host cell deposited under DSM 26762; and

b) a carrier or excipient.

3. A monoclonal antibody composition comprising:

a) an isolated monoclonal antibody that specifically binds to 025b antigen of multi drug resistant (MDR) E. coli strains which comprises:

the variable region of the antibody light chain produced by the host cell deposited under DSM 28171; and

the variable region of the antibody heavy chain produced by the host cell deposited under DSM 28172; and

b) a carrier or excipient.

4. A pharmaceutical preparation of an antibody of claim 1 , comprising a parenteral or mucosal formulation, containing a pharmaceutically acceptable carrier or excipient.

5. A diagnostic preparation of an antibody of claim 1 containing the antibody with a label and/or a further diagnostic reagent with a label and/or a solid phase to immobilize at least one of the antibody and the diagnostic reagent.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2022
From: X4 PHARMACEUTICALS, INC.; X4 PHARMACEUTICALS (AUSTRIA) GMBH
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 059518/0957 →
LICENSE Recorded Sep 14, 2020
From: X4 PHARMACEUTICALS (AUSTRIA) GMBH
To: JANSSEN PHARMACEUTICALS INC.,
Reel/Frame 053769/0930 →
CHANGE OF NAME Recorded Oct 8, 2019
From: ARSANIS BIOSCIENCES GMBH
To: X4 PHARMACEUTICALS (AUSTRIA) GMBH
Reel/Frame 050671/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2015
From: ESZTER, NAGY; NAGY, GABOR; SZIJARTO, VALERIA; MAGYARICS, ZOLTAN; MIRKINA, IRINA; GUACHALLA, LUIS; BADARAU, ADRIANA; ZAUNER, GERHILD; LUKASIEWICZ, JOLANTA
To: ARSANIS BIOSCIENCES GMBH
Reel/Frame 035890/0534 →
Priority Claims (1)
EP 13151627 · Jan 17, 2013 · regional
Continuity (1)
Related Publication 20150322138A1 · Nov 12, 2015